What Semaglutide Does to Your Body, Step by Step

Step 1: Binding to GLP-1 receptors, what happens in the first hours

After each weekly injection, semaglutide circulates in the bloodstream and binds to GLP-1 receptors distributed across the brain, gut and pancreas. GLP-1 (glucagon-like peptide-1) is a hormone your intestine releases naturally when you eat, but it breaks down within minutes. Semaglutide is engineered to last a full week, so the signal it carries ("food has arrived, adjust accordingly") stays active continuously rather than fading after each meal.

In the pancreas, that signal prompts insulin secretion when blood glucose rises, and suppresses glucagon, the hormone that tells the liver to release stored sugar. For people without diabetes this keeps glucose well-regulated throughout the day. For people with type 2 diabetes it can meaningfully improve blood sugar control, which is why semaglutide was first licensed in that context.

You can read a plain-language account of these mechanisms on the NHS semaglutide medicines page, which covers both the weight-management and diabetes uses. Our own overview of semaglutide as a weight-loss treatment explains how these effects translate into the clinical results.

Step 2: The appetite shift, what changes in the brain and stomach over the following days

The part most people notice first is appetite. GLP-1 receptors in the hypothalamus (the brain region that governs hunger) receive a sustained signal that dampens the drive to eat. Meals feel satisfying sooner. The urge to snack between them weakens. Some people describe thinking about food noticeably less, not as a conscious effort but as a simple absence of the usual pull.

Alongside this, gastric emptying slows. Food moves more gradually from the stomach to the small intestine, which prolongs the physical sense of fullness. The two effects compound each other: you eat less at meals, feel full for longer, and the reward circuitry associated with eating becomes quieter. Research into the fuller range of effects semaglutide has on the body captures how broad these downstream changes can be.

These shifts are not immediate. Most people notice meaningful appetite reduction after two to four weeks, once the dose has stabilised. The treatment schedule starts at a low dose to let the body adjust gradually, gastrointestinal side effects are most common in the early weeks and generally ease as the body acclimates. Nausea, loose stools, constipation and indigestion are the most frequently reported, particularly after a dose increase.

Step 3: Weight change and what the body adapts to over weeks and months

As calorie intake falls in response to reduced appetite, the body draws on stored fat for energy. Weight loss in clinical trials was gradual and cumulative. The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity or overweight for 68 weeks; those taking semaglutide 2.4 mg alongside a lifestyle programme lost an average of around 15% of body weight, versus about 2.4% for placebo. Results vary between individuals, body weight, baseline metabolic rate, adherence and lifestyle factors all play a role.

A practical habit worth building early: weigh yourself on the same scales, on the same morning each week, before eating. Weekly rather than daily readings smooth out the normal day-to-day fluctuations that can obscure a real downward trend. It takes under a minute and gives you and your prescriber a cleaner picture of how your body is responding. If you would like to understand how Wegovy works in the body, that page walks through the mechanisms in accessible detail, and covers what changes you might expect at each stage of treatment. If you are curious about what Wegovy does to your body, that page looks at the mechanisms in detail.

Beyond weight, sustained treatment has been associated with improvements in blood pressure, cholesterol profiles and markers of insulin resistance in trial populations, though these are secondary benefits and not the licensed indication for weight management.

Safety, monitoring, and when to get medical help

Because semaglutide is a prescription-only medicine, the process of getting it includes a clinical assessment of your full health picture: current medicines, relevant conditions and BMI. The Wegovy treatment overview covers the licensed eligibility criteria in the UK. Semaglutide is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive; it is also not licensed for under-18s.

Most side effects are gastrointestinal and settle within the first few weeks at any given dose. There are, however, signs that warrant prompt medical attention: severe stomach pain (particularly if it reaches into your back, with or without vomiting) should be assessed without delay, as this can occasionally indicate pancreatitis, an infrequent but serious reaction flagged in MHRA safety communications. Gallbladder symptoms, signs of dehydration from persistent vomiting or diarrhoea, and any allergic reaction should also prompt contact with a healthcare professional. You can report any suspected side effect directly via the MHRA Yellow Card scheme.

If you have questions about whether semaglutide is appropriate for your situation, our frequently asked questions cover common scenarios, and our prescribers are available seven days a week through the aftercare line. For a broader look at weight-loss treatment options available in the UK, that page covers the landscape clearly. If you are curious about whether combining supplements with your treatment is safe, our page on apple cider vinegar and Wegovy addresses that question directly.